drTarget portfolio target-disease associations for genetic disorders DrTarget’s AI-Powered Indication Expansion for Genetic Disorders

DrTarget’s AI-Driven Approach to Genetic Disorders

DrTarget applies cutting-edge AI and machine learning to uncover target-disease associations for genetic disorders, leveraging data from ChEMBL, PubChem, Open Targets and other repositories. Our computational models identify novel therapeutic targets and drug repurposing opportunities for a wide range of inherited conditions, including:

✔ Monogenic and Polygenic Disorders
✔ Rare Genetic Diseases
✔ Neuromuscular Disorders
✔ Metabolic Syndromes with Genetic Origins
✔ Hereditary Cancer Syndromes

By integrating genomic data, pathway analysis, and AI-powered drug discovery, we pinpoint key molecular mechanisms involved in disease onset and progression. This enables a precision medicine approach, supporting the development of targeted therapies that align with the latest advances in genetics.

Target-disease associations for genetic disorders.

Check best scored target-disease associations in table:

BioAssay Name	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	azoospermia	targetBased	343786	1253	0.623836516059577	139
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	azoospermia	targetBased	296501	2737	0.623836516059577	139
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	azoospermia	targetBased	64908	1225	0.619951507505911	67
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	azoospermia	targetBased	64908	359	0.619951507505911	67
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	reproductive system disease	targetBased	86095	1442	0.556069929669968	1974
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	reproductive system disease	targetBased	86095	1151	0.556069929669968	1974
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	reproductive system disease	targetBased	86095	1114	0.504093319777361	503
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	infertility	targetBased	86095	1442	0.673498662347584	318
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	infertility	targetBased	86095	1151	0.673498662347584	318
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	infertility	targetBased	394050	3624	0.527380594556525	28
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	infertility	targetBased	86095	1114	0.537453046426094	68
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	infertility	targetBased	359518	300	0.622704166546388	26
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	infertility	targetBased	335652	1779	0.622704166546388	26
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	infertility	targetBased	357537	806	0.622704166546388	26
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	infertility	targetBased	339887	1178	0.622704166546388	26
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	infertility	targetBased	362274	1056	0.622704166546388	26
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	infertility	targetBased	336308	6862	0.622704166546388	26
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	infertility	targetBased	364051	9106	0.60466648961276	9
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	infertility	targetBased	407539	2380	0.60466648961276	9
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	infertility	targetBased	407539	2380	0.60466648961276	9
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	injury	targetBased	335239	991	0.63920957677244	77
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	injury	targetBased	335239	695	0.63920957677244	77
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	polycystic ovary syndrome	targetBased	86095	1442	0.691019361968048	297
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	polycystic ovary syndrome	targetBased	86095	1151	0.691019361968048	297
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	injury	targetBased	339297	1446	0.568124714348561	40
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	injury	targetBased	316642	617	0.607137392360614	85
uHTS identification of small molecule modulators of NR3A	GRIN3A	injury	targetBased	339772	8480	0.639553777527006	41
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	polycystic ovary syndrome	targetBased	394050	3624	0.593532835555096	107
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	polycystic ovary syndrome	targetBased	405130	6428	0.602415032685796	174
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	polycystic ovary syndrome	targetBased	373462	23	0.602415032685796	174
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	polycystic ovary syndrome	targetBased	405130	6428	0.602415032685796	174
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	99314	335	0.615267644013478	263
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	196176	782	0.615267644013478	263
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	99314	390	0.615267644013478	263
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	196177	811	0.615267644013478	263
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	196176	670	0.615267644013478	263
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	polycystic ovary syndrome	targetBased	196177	519	0.615267644013478	263
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	polycystic ovary syndrome	targetBased	639428	9218	0.515572552941364	60
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	irritable bowel syndrome	targetBased	335239	991	0.609584926847712	24
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	irritable bowel syndrome	targetBased	335239	695	0.609584926847712	24
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	99314	335	0.571601682713427	23
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	196176	782	0.571601682713427	23
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	99314	390	0.571601682713427	23
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	196177	811	0.571601682713427	23
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	196176	670	0.571601682713427	23
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	196177	519	0.571601682713427	23
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	irritable bowel syndrome	targetBased	359207	1189	0.578284034396309	9
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	irritable bowel syndrome	targetBased	63676	1938	0.578284034396309	9
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	irritable bowel syndrome	targetBased	359207	316	0.578284034396309	9
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	irritable bowel syndrome	targetBased	63656	2179	0.578284034396309	9
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	irritable bowel syndrome	targetBased	359207	4555	0.578284034396309	9
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	irritable bowel syndrome	targetBased	64908	366	0.557687575050289	12
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	irritable bowel syndrome	targetBased	61606	416	0.557687575050289	12
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	preeclampsia	targetBased	335531	328	0.637771450291283	22
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	preeclampsia	targetBased	339297	1446	0.611191772523636	20
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	Sjogren syndrome	targetBased	343468	734	0.549959690731184	17
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	endometriosis	targetBased	86095	1442	0.608846056713265	568
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	endometriosis	targetBased	86095	1151	0.608846056713265	568
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	age-related macular degeneration	targetBased	343467	1710	0.607810318811785	669
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	kidney disease	targetBased	394050	3624	0.558942391032917	360
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	kidney disease	targetBased	335531	328	0.529475545353634	15
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	kidney disease	targetBased	324747	813	0.555299935898777	14
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	pregnancy	targetBased	86095	1442	0.613137664988923	15
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	pregnancy	targetBased	86095	1151	0.613137664988923	15
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	pregnancy	targetBased	335239	991	0.612682141130405	20
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	pregnancy	targetBased	335239	695	0.612682141130405	20
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	pregnancy	targetBased	339297	1446	0.586792686121393	9
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	pregnancy	targetBased	324747	1043	0.612946296670552	11
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	essential tremor	targetBased	385746	932	0.749984466437818	387
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	essential tremor	targetBased	364051	9106	0.501948282330665	41
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	essential tremor	targetBased	407539	2380	0.501948282330665	41
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	essential tremor	targetBased	407539	2380	0.501948282330665	41
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	Behcet's syndrome	targetBased	292323	1836	0.542016081643006	30
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	ischemia reperfusion injury	targetBased	305610	3794	0.588528225678562	8
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	ischemia reperfusion injury	targetBased	339674	2841	0.588528225678562	8
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	chronic kidney disease	targetBased	290355	265	0.515099145760397	31
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	chronic kidney disease	targetBased	394050	3624	0.680879493325072	458
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic kidney disease	targetBased	99314	335	0.597603837168746	188
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic kidney disease	targetBased	196176	782	0.597603837168746	188
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic kidney disease	targetBased	99314	390	0.597603837168746	188
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic kidney disease	targetBased	196177	811	0.597603837168746	188
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic kidney disease	targetBased	196176	670	0.597603837168746	188
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	chronic kidney disease	targetBased	196177	519	0.597603837168746	188
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	vitamin D deficiency	targetBased	394050	3624	0.66393764534113	198
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	chronic kidney disease	targetBased	335239	991	0.510228231583128	12
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	chronic kidney disease	targetBased	335239	695	0.510228231583128	12
Factor XIa 1536 HTS	F11_modulation	deep vein thrombosis	targetBased	218707	302	0.55243395918738	42
Thrombin 1536 HTS	F2_modulation	deep vein thrombosis	targetBased	217233	557	0.640640436953824	362
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	acne	targetBased	86095	1442	0.659027038178219	60
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	acne	targetBased	86095	1151	0.659027038178219	60
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	acne	targetBased	394050	3624	0.521174640201791	8
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	premature birth	targetBased	335531	328	0.62556973411477	24
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	premature birth	targetBased	324747	1043	0.616021785259648	29
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	eye disease	targetBased	92518	501	0.518999582067646	50
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	erectile dysfunction	targetBased	250190	1304	0.614214142126277	12
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	erectile dysfunction	targetBased	255537	2141	0.614214142126277	12
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	nephrolithiasis	targetBased	335239	991	0.602212906787968	11
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	nephrolithiasis	targetBased	335239	695	0.602212906787968	11
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	nephrolithiasis	targetBased	335531	328	0.5424462695145	8
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	nephrolithiasis	targetBased	195560	517	0.502807214536861	17
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	open-angle glaucoma	targetBased	59788	212	0.616661170668676	21
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	gastroesophageal reflux disease	targetBased	359518	300	0.611643521081338	12
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	gastroesophageal reflux disease	targetBased	335652	1779	0.611643521081338	12
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	gastroesophageal reflux disease	targetBased	357537	806	0.611643521081338	12
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	gastroesophageal reflux disease	targetBased	339887	1178	0.611643521081338	12
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	gastroesophageal reflux disease	targetBased	362274	1056	0.611643521081338	12
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gastroesophageal reflux disease	targetBased	336308	6862	0.611643521081338	12
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	nephrotic syndrome	targetBased	305610	382	0.564523814927137	122
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	nephrotic syndrome	targetBased	305610	3253	0.564523814927137	122
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	focal segmental glomerulosclerosis	targetBased	305610	382	0.875186084052801	548
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	focal segmental glomerulosclerosis	targetBased	305610	3253	0.875186084052801	548
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	open-angle glaucoma	targetBased	359207	1189	0.569561257660925	6
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	open-angle glaucoma	targetBased	63676	1938	0.569561257660925	6
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	open-angle glaucoma	targetBased	359207	316	0.569561257660925	6
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	open-angle glaucoma	targetBased	63656	2179	0.569561257660925	6
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	open-angle glaucoma	targetBased	359207	4555	0.569561257660925	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	open-angle glaucoma	targetBased	339297	1446	0.668093484041488	190
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	alopecia areata	targetBased	217959	2390	0.554940346190329	45
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	IGA glomerulonephritis	targetBased	343468	734	0.596885730731305	83
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	anthropometric measurement	targetBased	356160	3470	0.708890420062797	443
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	anthropometric measurement	targetBased	356160	1703	0.708890420062797	443
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	waist circumference	targetBased	356160	3470	0.758230714129653	50
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	waist circumference	targetBased	356160	1703	0.758230714129653	50
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	erythrocyte count	targetBased	86095	1114	0.538077017074459	11
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	erythrocyte count	targetBased	276265	806	0.512458045532973	12
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	primary ovarian insufficiency	targetBased	86095	1442	0.660662625776492	198
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	primary ovarian insufficiency	targetBased	86095	1151	0.660662625776492	198
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	primary ovarian insufficiency	targetBased	64908	1225	0.768831049962756	66
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	primary ovarian insufficiency	targetBased	64908	359	0.768831049962756	66
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	primary ovarian insufficiency	targetBased	86095	1114	0.575632336673213	51
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male infertility	targetBased	64908	1225	0.579314160133462	144
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male infertility	targetBased	64908	359	0.579314160133462	144
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	birth weight	targetBased	86095	1442	0.52265879869217	12
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	birth weight	targetBased	86095	1151	0.52265879869217	12
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	leukocyte count	targetBased	339297	1446	0.506555108845403	36
qHTS for Inhibitors of TGF-b	TGFB1	anemia (phenotype)	pathwayBased	403345	4970	0.524892488999053	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	anemia (phenotype)	targetBased	394050	3624	0.583287797794901	8
Primary HTS Assay for S1P3 Antagonists	S1PR3	leukocyte count	targetBased	169141	462	0.516140572346041	39
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	leukocyte count	targetBased	96879	447	0.540782639544795	27
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	leukocyte count	targetBased	96879	207	0.540782639544795	27
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	platelet count	targetBased	217959	2390	0.781132669160644	77
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	hematocrit	targetBased	363840	2624	0.507214442929743	62
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	platelet count	targetBased	330392	1295	0.503196509516558	9
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	hematocrit	targetBased	86095	1114	0.539606154049657	12
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	platelet count	targetBased	314998	2199	0.503049386602255	26
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	platelet count	targetBased	642362	5830	0.513483389362432	9
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	platelet count	targetBased	331360	2760	0.513483389362432	9
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	leukocyte count	targetBased	326888	645	0.560601777458065	76
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	leukocyte count	targetBased	217959	771	0.720998711707685	68
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	leukocyte count	targetBased	217959	569	0.720998711707685	68
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	hematocrit	targetBased	642362	5830	0.512591213709501	11
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	hematocrit	targetBased	331360	2760	0.512591213709501	11
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	lymphocyte count	targetBased	326888	645	0.552482559460344	41
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	lymphocyte count	targetBased	322361	619	0.510858872706143	13
Primary HTS assay for chemical inhibitors of TNF alpha stimulated VCAM1 expression	VCAM1_expression	lymphocyte count	targetBased	94498	457	0.52226432746613	21
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	C-reactive protein measurement	targetBased	330392	1295	0.589598524652379	30
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	C-reactive protein measurement	targetBased	356160	3470	0.509064091101982	9
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	C-reactive protein measurement	targetBased	356160	1703	0.509064091101982	9
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	mean corpuscular hemoglobin	targetBased	276265	806	0.527919870832325	21
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	body height	pathwayBased	64908	979	0.551680303826237	14
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	body height	pathwayBased	64908	278	0.551680303826237	14
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	alkaline phosphatase measurement	targetBased	639428	9218	0.501543697849377	18
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	lymphocyte count	targetBased	55710	315	0.583691959694125	53
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	alkaline phosphatase measurement	targetBased	195560	517	0.791261379108031	93
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	body height	targetBased	86095	1442	0.633664584736138	47
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	body height	targetBased	86095	1151	0.633664584736138	47
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	mean corpuscular hemoglobin concentration	targetBased	138717	842	0.531552989154815	14
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	mean corpuscular hemoglobin concentration	targetBased	276265	806	0.524565260505853	15
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	mean corpuscular hemoglobin concentration	targetBased	325630	216	0.510821888035741	32
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	telomere length	targetBased	322361	619	0.650168587201349	33
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	hemoglobin measurement	targetBased	363840	2624	0.528898317686333	73
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	body height	targetBased	343467	1710	0.631175554191538	20
HTS of Smad transcription factor inhibitors	SMAD3	body height	targetBased	88033	251	0.515300145843167	11
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	body height	targetBased	31324	362	0.54316419394014	12
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hemoglobin measurement	targetBased	99314	335	0.5118851697251	28
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hemoglobin measurement	targetBased	196176	782	0.5118851697251	28
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hemoglobin measurement	targetBased	99314	390	0.5118851697251	28
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hemoglobin measurement	targetBased	196177	811	0.5118851697251	28
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hemoglobin measurement	targetBased	196176	670	0.5118851697251	28
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hemoglobin measurement	targetBased	196177	519	0.5118851697251	28
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	hemoglobin measurement	targetBased	86095	1114	0.55712159008365	14
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	hemoglobin measurement	targetBased	642362	5830	0.570577910064087	16
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	hemoglobin measurement	targetBased	331360	2760	0.570577910064087	16
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	apolipoprotein A 1 measurement	targetBased	319204	3065	0.654585106434475	18
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	apolipoprotein A 1 measurement	targetBased	316970	306	0.654585106434475	18
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	serum gamma-glutamyl transferase measurement	pathwayBased	7671	874	0.630287012112818	11
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	serum gamma-glutamyl transferase measurement	targetBased	304060	10600	0.630287012112818	11
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	serum gamma-glutamyl transferase measurement	pathwayBased	305439	16717	0.630287012112818	11
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	mean corpuscular volume	targetBased	319204	3065	0.513853241245553	11
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	mean corpuscular volume	targetBased	316970	306	0.513853241245553	11
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	mean corpuscular volume	targetBased	138717	842	0.507486032664877	11
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	mean corpuscular volume	pathwayBased	193265	3100	0.514100334861674	12
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	mean corpuscular volume	pathwayBased	359244	3094	0.514100334861674	12
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	fibrinogen measurement	targetBased	369953	760	0.558074033786004	29
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	fibrinogen measurement	targetBased	369953	498	0.558074033786004	29
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	IGF-1 measurement	targetBased	217959	2390	0.742703261668942	36
qHTS for Inhibitors of Glutaminase (GLS)	GLS	mean platelet volume	targetBased	405291	844	0.508735256331516	15
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	mean corpuscular volume	targetBased	276265	806	0.537191446714195	32
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	mean corpuscular volume	targetBased	325630	216	0.533529352493559	83
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	mean corpuscular volume	targetBased	340696	540	0.522587039922814	26
Factor XIa 1536 HTS	F11_modulation	coagulation factor measurement	targetBased	218707	302	0.515638045408026	6
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	sexual dysfunction	targetBased	86095	1442	0.547899973728238	18
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	sexual dysfunction	targetBased	86095	1151	0.547899973728238	18
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	sexual dysfunction	targetBased	86095	1114	0.516153972197123	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	sexual dysfunction	targetBased	359518	300	0.509695304165687	17
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	sexual dysfunction	targetBased	335652	1779	0.509695304165687	17
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	sexual dysfunction	targetBased	357537	806	0.509695304165687	17
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	sexual dysfunction	targetBased	339887	1178	0.509695304165687	17
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	sexual dysfunction	targetBased	362274	1056	0.509695304165687	17
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	sexual dysfunction	targetBased	336308	6862	0.509695304165687	17
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	sexual dysfunction	targetBased	356160	3470	0.595062731184444	18
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	sexual dysfunction	targetBased	356160	1703	0.595062731184444	18
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	post operative nausea and vomiting	targetBased	363803	2412	0.612103153859535	24
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	post operative nausea and vomiting	targetBased	335239	991	0.577168330395272	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	post operative nausea and vomiting	targetBased	335239	695	0.577168330395272	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	post operative nausea and vomiting	targetBased	359518	300	0.644129386558569	38
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	post operative nausea and vomiting	targetBased	335652	1779	0.644129386558569	38
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	post operative nausea and vomiting	targetBased	357537	806	0.644129386558569	38
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	post operative nausea and vomiting	targetBased	339887	1178	0.644129386558569	38
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	post operative nausea and vomiting	targetBased	362274	1056	0.644129386558569	38
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	post operative nausea and vomiting	targetBased	336308	6862	0.644129386558569	38
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	post operative nausea and vomiting	targetBased	364051	9106	0.602553424206921	21
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	post operative nausea and vomiting	targetBased	407539	2380	0.602553424206921	21
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	post operative nausea and vomiting	targetBased	407539	2380	0.602553424206921	21
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	post operative nausea and vomiting	targetBased	335239	2035	0.515680643226986	9
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	post operative nausea and vomiting	targetBased	335239	279	0.515680643226986	9
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	post operative nausea and vomiting	targetBased	359207	1189	0.612946296670552	11
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	post operative nausea and vomiting	targetBased	63676	1938	0.612946296670552	11
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	post operative nausea and vomiting	targetBased	359207	316	0.612946296670552	11
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	post operative nausea and vomiting	targetBased	63656	2179	0.612946296670552	11
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	post operative nausea and vomiting	targetBased	359207	4555	0.612946296670552	11
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	post operative nausea and vomiting	targetBased	64908	446	0.515680643226986	9
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	post operative nausea and vomiting	targetBased	64908	641	0.515680643226986	9
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	post operative nausea and vomiting	targetBased	64908	366	0.519892362582376	12
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	post operative nausea and vomiting	targetBased	61606	416	0.519892362582376	12
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	neutrophil count	targetBased	326888	645	0.517363544154237	15
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	neutrophil count	targetBased	217959	771	0.670237943777037	29
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	neutrophil count	targetBased	217959	569	0.670237943777037	29
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	sex hormone-binding globulin measurement	targetBased	360873	7438	0.503853378066006	11
qHTS of Nrf2 Activators	Nrf2 activators	sex hormone-binding globulin measurement	pathwayBased	403871	1243	0.503853378066006	11
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	sex hormone-binding globulin measurement	targetBased	217035	883	0.527559111681462	30
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	99314	335	0.517365234928652	33
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	196176	782	0.517365234928652	33
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	99314	390	0.517365234928652	33
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	196177	811	0.517365234928652	33
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	196176	670	0.517365234928652	33
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	sex hormone-binding globulin measurement	targetBased	196177	519	0.517365234928652	33
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	sex hormone-binding globulin measurement	targetBased	639428	9218	0.512797449636891	11
qHTS Assay for NPC1 Promoter Activators	NPC1	neutrophil count	pathwayBased	320682	7575	0.519531683761622	21
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	neutrophil count	targetBased	330392	1295	0.517196008031586	27
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	neutrophil count	targetBased	369953	760	0.541800422744609	11
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	neutrophil count	targetBased	369953	498	0.541800422744609	11
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	sex hormone-binding globulin measurement	targetBased	276265	806	0.534121828195915	12
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	calcium measurement	targetBased	195560	517	0.59105234661804	15
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	serum alanine aminotransferase measurement	targetBased	217035	883	0.522832199327453	11
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	serum alanine aminotransferase measurement	targetBased	99314	335	0.515407329254512	20
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	serum alanine aminotransferase measurement	targetBased	196176	782	0.515407329254512	20
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	serum alanine aminotransferase measurement	targetBased	99314	390	0.515407329254512	20
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	serum alanine aminotransferase measurement	targetBased	196177	811	0.515407329254512	20
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	serum alanine aminotransferase measurement	targetBased	196176	670	0.515407329254512	20
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	serum alanine aminotransferase measurement	targetBased	196177	519	0.515407329254512	20
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	hip circumference	targetBased	356160	3470	0.764439035227678	48
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	hip circumference	targetBased	356160	1703	0.764439035227678	48
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	eosinophil count	targetBased	217959	2390	0.563353850272379	31
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	eosinophil count	pathwayBased	193265	3100	0.513404591520698	15
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	eosinophil count	pathwayBased	359244	3094	0.513404591520698	15
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	eosinophil count	targetBased	326888	645	0.514078667291535	14
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	eosinophil count	targetBased	75924	1804	0.546168104715194	45
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	eosinophil count	targetBased	99314	335	0.529196236886013	22
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	eosinophil count	targetBased	196176	782	0.529196236886013	22
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	eosinophil count	targetBased	99314	390	0.529196236886013	22
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	eosinophil count	targetBased	196177	811	0.529196236886013	22
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	eosinophil count	targetBased	196176	670	0.529196236886013	22
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	eosinophil count	targetBased	196177	519	0.529196236886013	22
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	aspartate aminotransferase measurement	targetBased	217035	883	0.51056837906566	8
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	eosinophil count	targetBased	73174	1034	0.724336231239081	52
HTS of Smad transcription factor inhibitors	SMAD3	eosinophil count	targetBased	88033	251	0.562408491365278	42
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	eosinophil count	targetBased	339297	1446	0.541528896921096	26
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	eosinophil count	targetBased	217959	771	0.669089535404003	25
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	eosinophil count	targetBased	217959	569	0.669089535404003	25
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	protein measurement	pathwayBased	64908	979	0.528788155725603	31
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	protein measurement	pathwayBased	64908	278	0.528788155725603	31
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	monocyte count	pathwayBased	193265	3100	0.500249908552602	11
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	monocyte count	pathwayBased	359244	3094	0.500249908552602	11
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	monocyte count	targetBased	326888	645	0.563653416927251	46
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	monocyte count	targetBased	217959	771	0.665324642173597	28
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	monocyte count	targetBased	217959	569	0.665324642173597	28
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	monocyte count	targetBased	325630	216	0.525053140584303	46
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	appendicular lean mass	targetBased	356160	3470	0.666466888144041	17
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	appendicular lean mass	targetBased	356160	1703	0.666466888144041	17
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	protein measurement	targetBased	305610	3794	0.557707909379901	37
Primary HTS Assay for S1P3 Antagonists	S1PR3	monocyte count	targetBased	169141	462	0.583242928597541	38
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	monocyte count	targetBased	96879	447	0.56162009245327	10
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	monocyte count	targetBased	96879	207	0.56162009245327	10
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	microphthalmia	targetBased	362098	692	0.510387699900412	12
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	post-operative sign or symptom	targetBased	335239	991	0.621738874881876	17
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	post-operative sign or symptom	targetBased	335239	695	0.621738874881876	17
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	post-operative sign or symptom	targetBased	305610	3794	0.541614541812703	9
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	post-operative sign or symptom	targetBased	339674	2841	0.541614541812703	9
uHTS identification of small molecule modulators of NR3A	GRIN3A	post-operative sign or symptom	targetBased	339772	8480	0.553175059504274	7
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	hematologic disease	targetBased	217959	2390	0.756268849901468	5543
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	ovarian disease	pathwayBased	376029	3978	0.573470389432472	7344
Factor XIIa 1536 HTS	F12_modulation	urticaria	targetBased	217430	649	0.546000964662808	58
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	urticaria	targetBased	339297	1446	0.598573318267027	11
Factor XIIa 1536 HTS	F12_modulation	angioedema	targetBased	217430	649	0.594448014117014	64
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	vitamin deficiency	targetBased	394050	3624	0.508869431197495	75
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	cycloplegia	targetBased	359207	1189	0.631704381295873	17
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	cycloplegia	targetBased	63676	1938	0.631704381295873	17
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	cycloplegia	targetBased	359207	316	0.631704381295873	17
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	cycloplegia	targetBased	63656	2179	0.631704381295873	17
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	cycloplegia	targetBased	359207	4555	0.631704381295873	17
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Chemotherapy-induced nausea and vomiting	targetBased	363803	2412	0.602828840473753	32
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Chemotherapy-induced nausea and vomiting	targetBased	359518	300	0.603698410819204	33
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Chemotherapy-induced nausea and vomiting	targetBased	335652	1779	0.603698410819204	33
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Chemotherapy-induced nausea and vomiting	targetBased	357537	806	0.603698410819204	33
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Chemotherapy-induced nausea and vomiting	targetBased	339887	1178	0.603698410819204	33
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Chemotherapy-induced nausea and vomiting	targetBased	362274	1056	0.603698410819204	33
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Chemotherapy-induced nausea and vomiting	targetBased	336308	6862	0.603698410819204	33
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	Chemotherapy-induced nausea and vomiting	targetBased	364051	9106	0.60185244135153	30
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	Chemotherapy-induced nausea and vomiting	targetBased	407539	2380	0.60185244135153	30
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	Chemotherapy-induced nausea and vomiting	targetBased	407539	2380	0.60185244135153	30
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	motion sickness	targetBased	359207	1189	0.58943430842421	23
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	motion sickness	targetBased	63676	1938	0.58943430842421	23
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	motion sickness	targetBased	359207	316	0.58943430842421	23
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	motion sickness	targetBased	63656	2179	0.58943430842421	23
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	motion sickness	targetBased	359207	4555	0.58943430842421	23
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	parental longevity	pathwayBased	376029	3978	0.625504964820304	18
Factor XIa 1536 HTS	F11_modulation	blood protein measurement	targetBased	218707	302	0.555401607966835	76
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	blood protein measurement	targetBased	75924	1804	0.512519522163457	23
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	blood protein measurement	pathwayBased	140118	236	0.500923769056078	6
qHTS of alpha-syn Inhibitors	SNCA	blood protein measurement	pathwayBased	368791	501	0.500923769056078	6
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	myeloid white cell count	targetBased	326888	645	0.513455010475936	27
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	monocyte percentage of leukocytes	targetBased	326888	645	0.500311638356786	12
Primary HTS Assay for S1P3 Antagonists	S1PR3	monocyte percentage of leukocytes	targetBased	169141	462	0.534418257486305	9
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	eosinophil percentage of leukocytes	targetBased	217959	771	0.57119427655971	11
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	eosinophil percentage of leukocytes	targetBased	217959	569	0.57119427655971	11
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	eosinophil percentage of leukocytes	targetBased	73174	1034	0.706952569843882	27
HTS of Smad transcription factor inhibitors	SMAD3	eosinophil percentage of leukocytes	targetBased	88033	251	0.5357359281835	15
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	platelet crit	targetBased	217959	2390	0.768707774378392	50
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	lymphocyte percentage of leukocytes	targetBased	55710	315	0.512208341739393	15
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	lymphocyte percentage of leukocytes	targetBased	217959	2390	0.524444660668715	9
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	reticulocyte count	targetBased	326888	645	0.518931501685393	11
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	reticulocyte count	targetBased	362098	692	0.672855333065367	30
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	reticulocyte count	targetBased	96879	447	0.603933460546532	39
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	reticulocyte count	targetBased	96879	207	0.603933460546532	39
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	reticulocyte count	targetBased	276265	806	0.520785206171264	20
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	reticulocyte count	targetBased	325630	216	0.510475068680431	24
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	dyspepsia	targetBased	359518	300	0.614594595559056	21
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	dyspepsia	targetBased	335652	1779	0.614594595559056	21
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	dyspepsia	targetBased	357537	806	0.614594595559056	21
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	dyspepsia	targetBased	339887	1178	0.614594595559056	21
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	dyspepsia	targetBased	362274	1056	0.614594595559056	21
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	dyspepsia	targetBased	336308	6862	0.614594595559056	21
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	poisoning	targetBased	359207	1189	0.57993179479527	9
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	poisoning	targetBased	63676	1938	0.57993179479527	9
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	poisoning	targetBased	359207	316	0.57993179479527	9
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	poisoning	targetBased	63656	2179	0.57993179479527	9
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	poisoning	targetBased	359207	4555	0.57993179479527	9
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Estrogen resistance syndrome	targetBased	86095	1442	0.62458590288883	44
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Estrogen resistance syndrome	targetBased	86095	1151	0.62458590288883	44
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	female infertility	targetBased	86095	1442	0.621559948320993	104
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	female infertility	targetBased	86095	1151	0.621559948320993	104
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	fecal incontinence	targetBased	335239	991	0.543359118242622	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	fecal incontinence	targetBased	335239	695	0.543359118242622	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	esophageal varices	targetBased	339297	1446	0.57280694202758	8
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	blood coagulation disease	targetBased	369953	760	0.57927882376402	97
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	blood coagulation disease	targetBased	369953	498	0.57927882376402	97
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	response to ivacaftor - efficacy	targetBased	343786	1253	0.634832430281935	48
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	response to ivacaftor - efficacy	targetBased	296501	2737	0.634832430281935	48
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	thrombophilia	targetBased	86095	1442	0.507615061227162	11
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	thrombophilia	targetBased	86095	1151	0.507615061227162	11
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	postpartum hemorrhage	targetBased	324747	1043	0.656394447196096	89
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	prophylactic surgery	pathwayBased	376029	3978	0.652727389691613	42
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	sprain	targetBased	316642	617	0.577168330395272	6
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	head injury	targetBased	324747	813	0.577168330395272	6
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	burn	targetBased	335239	991	0.513776057609053	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	burn	targetBased	335239	695	0.513776057609053	6
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	Red cell distribution width	targetBased	319204	3065	0.508248795307349	14
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	Red cell distribution width	targetBased	316970	306	0.508248795307349	14
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	Red cell distribution width	targetBased	276265	806	0.507420205788685	11
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	follow-up	pathwayBased	376029	3978	0.62497799817203	20
qHTS assay for re-activators of p53 using a Luc reporter	TP53	parp inhibitor response	pathwayBased	321427	201	0.519410926301161	6
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	parp inhibitor response	targetBased	54509	528	0.519410926301161	6
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	parp inhibitor response	targetBased	54513	338	0.519410926301161	6
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	parp inhibitor response	targetBased	125394	1890	0.519410926301161	6
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	parp inhibitor response	targetBased	124022	1156	0.519410926301161	6
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Red cell distribution width	targetBased	217959	2390	0.558888079392516	14
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	genetic non-acquired premature ovarian failure	targetBased	64908	1225	0.535151368505697	11
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	genetic non-acquired premature ovarian failure	targetBased	64908	359	0.535151368505697	11
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	bilateral oophorectomy	pathwayBased	376029	3978	0.622760631678199	15
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	reticulocyte measurement	targetBased	217959	2390	0.592574836962001	16
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	blood phosphate measurement	targetBased	195560	517	0.515354604839092	23
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	reticulocyte measurement	targetBased	362098	692	0.680245557576501	30
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	reticulocyte measurement	targetBased	96879	447	0.601816911607638	34
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	reticulocyte measurement	targetBased	96879	207	0.601816911607638	34
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	mean reticulocyte volume	targetBased	217959	2390	0.604514256128834	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	toxicity	targetBased	339297	1446	0.552250941038769	6
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	transient neonatal diabetes, dominant/recessive	targetBased	128695	1039	0.555971773589769	33
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	transient neonatal diabetes, dominant/recessive	targetBased	127961	1153	0.555971773589769	33
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	bronchoconstriction	targetBased	339297	1446	0.512930827305237	6
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	gastrointestinal disease	targetBased	290355	265	0.549751654009714	39
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gastrointestinal disease	targetBased	335239	991	0.626780891642088	146
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gastrointestinal disease	targetBased	335239	695	0.626780891642088	146
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	gastrointestinal disease	targetBased	359518	300	0.630154237489178	108
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	gastrointestinal disease	targetBased	335652	1779	0.630154237489178	108
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	gastrointestinal disease	targetBased	357537	806	0.630154237489178	108
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	gastrointestinal disease	targetBased	339887	1178	0.630154237489178	108
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	gastrointestinal disease	targetBased	362274	1056	0.630154237489178	108
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gastrointestinal disease	targetBased	336308	6862	0.630154237489178	108
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	gastrointestinal disease	targetBased	335531	328	0.552312264766224	68
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	gastrointestinal disease	targetBased	359207	1189	0.647353283120319	44
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	gastrointestinal disease	targetBased	63676	1938	0.647353283120319	44
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	gastrointestinal disease	targetBased	359207	316	0.647353283120319	44
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	gastrointestinal disease	targetBased	63656	2179	0.647353283120319	44
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	gastrointestinal disease	targetBased	359207	4555	0.647353283120319	44
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	phospholipids:total lipids ratio	targetBased	319204	3065	0.597188853998803	12
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	phospholipids:total lipids ratio	targetBased	316970	306	0.597188853998803	12
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selectiveÃ‚Â compounds	response to tramadol	targetBased	396029	13426	0.599617629702221	902
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selectiveÃ‚Â compounds	response to tramadol	targetBased	395981	5516	0.599617629702221	902
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	response to tramadol	targetBased	335239	991	0.5994368905986	695
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	response to tramadol	targetBased	335239	695	0.5994368905986	695
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	xerostomia	targetBased	359207	1189	0.602266958722854	14
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	xerostomia	targetBased	63676	1938	0.602266958722854	14
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	xerostomia	targetBased	359207	316	0.602266958722854	14
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	xerostomia	targetBased	63656	2179	0.602266958722854	14
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	xerostomia	targetBased	359207	4555	0.602266958722854	14
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	phosphate measurement	targetBased	195560	517	0.644251002036827	30
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male infertility with azoospermia or oligozoospermia due to single gene mutation	targetBased	64908	1225	0.71262050292756	170
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	male infertility with azoospermia or oligozoospermia due to single gene mutation	targetBased	64908	359	0.71262050292756	170
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	premature ejaculation	targetBased	335239	991	0.575894850070855	11
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	premature ejaculation	targetBased	335239	695	0.575894850070855	11
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Atrophy	targetBased	86095	1442	0.65174071862781	45
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Atrophy	targetBased	86095	1151	0.65174071862781	45
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Atrophy	targetBased	86095	1114	0.615694330133837	14
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Atrophic Vaginitis	targetBased	86095	1442	0.600186219790317	30
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Atrophic Vaginitis	targetBased	86095	1151	0.600186219790317	30
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Atrophic Vaginitis	targetBased	86095	1114	0.519892362582376	12
HTS for developing T Cell Immune Modulators	ITGAL	dry eye syndrome	targetBased	326271	221	0.648755531974305	36
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	dry eye syndrome	targetBased	92518	501	0.637763988057418	32
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	gastroparesis	targetBased	359518	300	0.609010949181426	33
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	gastroparesis	targetBased	335652	1779	0.609010949181426	33
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	gastroparesis	targetBased	357537	806	0.609010949181426	33
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	gastroparesis	targetBased	339887	1178	0.609010949181426	33
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	gastroparesis	targetBased	362274	1056	0.609010949181426	33
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gastroparesis	targetBased	336308	6862	0.609010949181426	33
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	overactive bladder	targetBased	86095	1442	0.516503334056033	9
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	overactive bladder	targetBased	86095	1151	0.516503334056033	9
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	overactive bladder	targetBased	86095	1114	0.518182524926282	6
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ocular hypertension	targetBased	59788	212	0.611084615406773	21
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ocular hypertension	targetBased	339297	1446	0.66025094772883	116
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	renal colic	targetBased	335239	991	0.619673100980468	18
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	renal colic	targetBased	335239	695	0.619673100980468	18
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	renal colic	targetBased	316642	617	0.546604802609276	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	acromegaly	targetBased	359518	300	0.625090953855627	21
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	acromegaly	targetBased	335652	1779	0.625090953855627	21
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	acromegaly	targetBased	357537	806	0.625090953855627	21
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	acromegaly	targetBased	339887	1178	0.625090953855627	21
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	acromegaly	targetBased	362274	1056	0.625090953855627	21
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	acromegaly	targetBased	336308	6862	0.625090953855627	21
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	acromegaly	targetBased	364051	9106	0.60466648961276	9
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	acromegaly	targetBased	407539	2380	0.60466648961276	9
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	acromegaly	targetBased	407539	2380	0.60466648961276	9
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Takayasu arteritis	targetBased	217959	2390	0.582949705673375	9
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	gastroenteritis	targetBased	359518	300	0.562663370717272	11
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	gastroenteritis	targetBased	335652	1779	0.562663370717272	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	gastroenteritis	targetBased	357537	806	0.562663370717272	11
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	gastroenteritis	targetBased	339887	1178	0.562663370717272	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	gastroenteritis	targetBased	362274	1056	0.562663370717272	11
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gastroenteritis	targetBased	336308	6862	0.562663370717272	11
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Menorrhagia	targetBased	86095	1442	0.516421046023942	9
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Menorrhagia	targetBased	86095	1151	0.516421046023942	9
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	Cleft palate	targetBased	290355	265	0.556037572799865	6
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Cleft palate	targetBased	335239	991	0.556037572799865	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Cleft palate	targetBased	335239	695	0.556037572799865	6
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Microcephaly	pathwayBased	70898	707	0.510065718520128	15
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Microcephaly	pathwayBased	131324	544	0.510065718520128	15
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	kidney failure	targetBased	305610	3794	0.583495942944549	11
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	kidney failure	targetBased	339674	2841	0.583495942944549	11
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	Microcephaly	targetBased	310014	1321	0.667110376709887	110
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ovulation	targetBased	86095	1442	0.519258439854514	11
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ovulation	targetBased	86095	1151	0.519258439854514	11
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	menopause	targetBased	86095	1442	0.662677082846212	180
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	menopause	targetBased	86095	1151	0.662677082846212	180
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	menopause	targetBased	86095	1114	0.647144623444855	81
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Eczematoid dermatitis	targetBased	217959	2390	0.560883027185879	20
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Hyperhidrosis	targetBased	359207	1189	0.619641488098591	45
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Hyperhidrosis	targetBased	63676	1938	0.619641488098591	45
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Hyperhidrosis	targetBased	359207	316	0.619641488098591	45
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Hyperhidrosis	targetBased	63656	2179	0.619641488098591	45
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Hyperhidrosis	targetBased	359207	4555	0.619641488098591	45
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	Hyperhidrosis	targetBased	363803	1450	0.619329000739565	41
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	Hyperhidrosis	targetBased	363803	2629	0.619329000739565	41
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	Hyperhidrosis	targetBased	363803	502	0.619329000739565	41
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	Hyperhidrosis	targetBased	363803	698	0.619329000739565	41
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	Hyperhidrosis	targetBased	363803	2133	0.619329000739565	41
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	Hyperhidrosis	targetBased	363803	1081	0.619329000739565	41
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	Pruritus	targetBased	290355	265	0.569007324270006	86
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	Deeply set eye	targetBased	310014	1321	0.559554695563483	14
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Myopia	targetBased	359207	1189	0.653717988912803	71
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Myopia	targetBased	63676	1938	0.653717988912803	71
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Myopia	targetBased	359207	316	0.653717988912803	71
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Myopia	targetBased	63656	2179	0.653717988912803	71
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Myopia	targetBased	359207	4555	0.653717988912803	71
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	Retinal dystrophy	targetBased	362026	1281	0.616194342273178	116
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	Retinal dystrophy	targetBased	314998	380	0.616194342273178	116
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Splenomegaly	targetBased	217959	2390	0.65073716130998	289
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Spasticity	targetBased	363803	2412	0.577168330395272	6
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Fever	targetBased	316642	617	0.666308468235629	115
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	Global developmental delay	targetBased	290915	2982	0.511899646334581	8
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	Global developmental delay	targetBased	359244	1307	0.511899646334581	8
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Thrombocytopenia	targetBased	217959	2390	0.510664605818772	117
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	Thrombocytopenia	targetBased	359244	2975	0.515889133368594	11
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	Thrombocytopenia	targetBased	215667	993	0.718968650475424	230
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	Thrombocytopenia	targetBased	218234	1620	0.718968650475424	230
Glucocerebrosidase	GBA1	Thrombocytopenia	targetBased	48118	549	0.508225184903392	29
Thrombin 1536 HTS	F2_modulation	Thrombocytopenia	targetBased	217233	557	0.653647579537218	492
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	Global developmental delay	targetBased	310014	1321	0.51395404279331	26
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Abnormal facial shape	pathwayBased	70898	707	0.563878136093242	11
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Abnormal facial shape	pathwayBased	131324	544	0.563878136093242	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Vomiting	targetBased	359518	300	0.607745142219739	20
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Vomiting	targetBased	335652	1779	0.607745142219739	20
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Vomiting	targetBased	357537	806	0.607745142219739	20
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Vomiting	targetBased	339887	1178	0.607745142219739	20
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Vomiting	targetBased	362274	1056	0.607745142219739	20
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Vomiting	targetBased	336308	6862	0.607745142219739	20
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	Diarrhea	targetBased	343786	1253	0.594015846742141	46
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	Diarrhea	targetBased	296501	2737	0.594015846742141	46
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Diarrhea	targetBased	335239	991	0.664483849517651	134
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Diarrhea	targetBased	335239	695	0.664483849517651	134
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	Diarrhea	targetBased	306502	3633	0.587578994481585	15
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	Diarrhea	targetBased	335180	1022	0.587578994481585	15
Factor XIa 1536 HTS	F11_modulation	Abnormal bleeding	targetBased	218707	302	0.536543143506856	12
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	Abnormal bleeding	targetBased	215667	993	0.558431392235399	18
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	Abnormal bleeding	targetBased	218234	1620	0.558431392235399	18
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Nausea and vomiting	targetBased	363803	2412	0.598733175441831	31
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Nausea and vomiting	targetBased	359518	300	0.644439340477792	58
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Nausea and vomiting	targetBased	335652	1779	0.644439340477792	58
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Nausea and vomiting	targetBased	357537	806	0.644439340477792	58
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Nausea and vomiting	targetBased	339887	1178	0.644439340477792	58
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Nausea and vomiting	targetBased	362274	1056	0.644439340477792	58
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Nausea and vomiting	targetBased	336308	6862	0.644439340477792	58
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	Nausea and vomiting	targetBased	364051	9106	0.597369836744691	29
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	Nausea and vomiting	targetBased	407539	2380	0.597369836744691	29
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	Nausea and vomiting	targetBased	407539	2380	0.597369836744691	29
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Nausea and vomiting	targetBased	359207	1189	0.554173663816071	11
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Nausea and vomiting	targetBased	63676	1938	0.554173663816071	11
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Nausea and vomiting	targetBased	359207	316	0.554173663816071	11
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Nausea and vomiting	targetBased	63656	2179	0.554173663816071	11
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Nausea and vomiting	targetBased	359207	4555	0.554173663816071	11
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Nausea	targetBased	335239	991	0.540462795734878	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Nausea	targetBased	335239	695	0.540462795734878	9
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Nausea	targetBased	359518	300	0.59173377598045	12
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Nausea	targetBased	335652	1779	0.59173377598045	12
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Nausea	targetBased	357537	806	0.59173377598045	12
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Nausea	targetBased	339887	1178	0.59173377598045	12
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Nausea	targetBased	362274	1056	0.59173377598045	12
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Nausea	targetBased	336308	6862	0.59173377598045	12
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	Constipation	targetBased	290355	265	0.609204549926413	18
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Constipation	targetBased	335239	991	0.662629221068349	183
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Constipation	targetBased	335239	695	0.662629221068349	183
Thrombin 1536 HTS	F2_modulation	Thromboembolism	targetBased	217233	557	0.563364509169008	126
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Hypothermia	targetBased	335239	991	0.577168330395272	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Hypothermia	targetBased	335239	695	0.577168330395272	6
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	Bilateral tonic-clonic seizure	targetBased	292323	567	0.662025642890829	123
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	Cholestasis	targetBased	343786	1253	0.511236770729013	31
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	Cholestasis	targetBased	296501	2737	0.511236770729013	31
qHTS for Inhibitors of TGF-b	TGFB1	Encephalopathy	pathwayBased	403345	4970	0.500700306923787	18
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Hyperkalemia	targetBased	339297	1446	0.553098988776931	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	Hypocalcemia	targetBased	394050	3624	0.652037636559681	45
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	Hyponatremia	targetBased	324747	813	0.599026253305242	24
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Hepatomegaly	targetBased	217959	2390	0.504139263648615	7
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Drooling	targetBased	359207	1189	0.51539889979238	8
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Drooling	targetBased	63676	1938	0.51539889979238	8
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Drooling	targetBased	359207	316	0.51539889979238	8
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Drooling	targetBased	63656	2179	0.51539889979238	8
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Drooling	targetBased	359207	4555	0.51539889979238	8
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Headache	targetBased	363803	2412	0.513896061529299	13
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Headache	targetBased	359518	300	0.60183546143348	19
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Headache	targetBased	335652	1779	0.60183546143348	19
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Headache	targetBased	357537	806	0.60183546143348	19
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Headache	targetBased	339887	1178	0.60183546143348	19
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Headache	targetBased	362274	1056	0.60183546143348	19
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Headache	targetBased	336308	6862	0.60183546143348	19
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Headache	targetBased	359207	1189	0.546604802609276	8
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Headache	targetBased	63676	1938	0.546604802609276	8
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Headache	targetBased	359207	316	0.546604802609276	8
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Headache	targetBased	63656	2179	0.546604802609276	8
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Headache	targetBased	359207	4555	0.546604802609276	8
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Premature ovarian insufficiency	targetBased	86095	1442	0.655812081846905	56
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Premature ovarian insufficiency	targetBased	86095	1151	0.655812081846905	56
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Headache	targetBased	316642	617	0.666642011690004	210
uHTS identification of small molecule modulators of NR3A	GRIN3A	Headache	targetBased	339772	8480	0.529395913623577	7
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Short stature	pathwayBased	70898	707	0.530962407119983	6
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Short stature	pathwayBased	131324	544	0.530962407119983	6
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	Myokymia	targetBased	305609	3405	0.597376524444087	35
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	Myokymia	targetBased	305600	1644	0.597376524444087	35
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Peptic ulcer	targetBased	359207	1189	0.624294296119937	14
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Peptic ulcer	targetBased	63676	1938	0.624294296119937	14
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Peptic ulcer	targetBased	359207	316	0.624294296119937	14
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Peptic ulcer	targetBased	63656	2179	0.624294296119937	14
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Peptic ulcer	targetBased	359207	4555	0.624294296119937	14
Thrombin 1536 HTS	F2_modulation	Recurrent thrombophlebitis	targetBased	217233	557	0.619285523949174	12
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Dyspareunia	targetBased	86095	1442	0.618373164314375	42
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Dyspareunia	targetBased	86095	1151	0.618373164314375	42
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Tip-toe gait	targetBased	322361	619	0.560405198256835	18
Factor XIIa 1536 HTS	F12_modulation	Reduced factor XII activity	targetBased	217430	649	0.577168330395272	6
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	Ascending aortic dissection	targetBased	75924	1804	0.534016505951106	8
Thrombin 1536 HTS	F2_modulation	Venous thrombosis	targetBased	217233	557	0.656248273264026	522
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Abnormal central motor function	targetBased	322361	619	0.585049361709701	59
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Mydriasis	targetBased	359207	1189	0.628351401578255	15
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Mydriasis	targetBased	63676	1938	0.628351401578255	15
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Mydriasis	targetBased	359207	316	0.628351401578255	15
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Mydriasis	targetBased	63656	2179	0.628351401578255	15
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Mydriasis	targetBased	359207	4555	0.628351401578255	15
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	Abdominal distention	targetBased	324747	813	0.60466648961276	9
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	Low alkaline phosphatase	targetBased	195560	517	0.51560110774517	24
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Myalgia	targetBased	316642	617	0.610462354553215	11
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Hot flashes	targetBased	86095	1442	0.556904492876028	15
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Hot flashes	targetBased	86095	1151	0.556904492876028	15
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Hypofibrinogenemia	targetBased	369953	760	0.586030436486814	33
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Hypofibrinogenemia	targetBased	369953	498	0.586030436486814	33
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	Feeding difficulties	targetBased	310014	1321	0.556048555043949	12
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Myelofibrosis	targetBased	217959	2390	0.636911227177659	1019
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Shock	targetBased	339297	1446	0.633272503785782	26
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	Abnormal pulmonary interstitial morphology	targetBased	326022	1334	0.519410926301161	6
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	Platelet-activating factor acetylhydrolase deficiency	targetBased	326024	4934	0.520209973681166	12
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Dysmenorrhea	targetBased	86095	1442	0.603589229933955	21
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Dysmenorrhea	targetBased	86095	1151	0.603589229933955	21
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	Abnormality of movement	targetBased	292323	567	0.513867929573946	8
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	Fatigue	targetBased	108286	1415	0.595643737097559	23
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Tics	targetBased	359518	300	0.508640410022131	20
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Tics	targetBased	335652	1779	0.508640410022131	20
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Tics	targetBased	357537	806	0.508640410022131	20
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Tics	targetBased	339887	1178	0.508640410022131	20
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Tics	targetBased	362274	1056	0.508640410022131	20
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Tics	targetBased	336308	6862	0.508640410022131	20
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Dysmenorrhea	targetBased	316642	617	0.603833765267521	17
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	disorder of sexual differentiation	targetBased	64908	1225	0.673726545644413	377
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	disorder of sexual differentiation	targetBased	64908	359	0.673726545644413	377
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	hypogonadism	targetBased	86095	1442	0.669694218698102	233
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	hypogonadism	targetBased	86095	1151	0.669694218698102	233
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	hypogonadism	targetBased	86095	1114	0.555819857005913	19
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	hypogonadism	targetBased	359518	300	0.626709780417037	43
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	hypogonadism	targetBased	335652	1779	0.626709780417037	43
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	hypogonadism	targetBased	357537	806	0.626709780417037	43
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	hypogonadism	targetBased	339887	1178	0.626709780417037	43
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	hypogonadism	targetBased	362274	1056	0.626709780417037	43
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	hypogonadism	targetBased	336308	6862	0.626709780417037	43
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	hypogonadism	targetBased	364051	9106	0.619285523949174	12
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	hypogonadism	targetBased	407539	2380	0.619285523949174	12
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	hypogonadism	targetBased	407539	2380	0.619285523949174	12
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	cholestasis	targetBased	343786	1253	0.512356311300188	11
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	cholestasis	targetBased	296501	2737	0.512356311300188	11
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	constipation disorder	targetBased	335239	991	0.577168330395272	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	constipation disorder	targetBased	335239	695	0.577168330395272	6
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	microphthalmia, isolated, with coloboma	targetBased	362098	692	0.50452073307516	9
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	hepatorenal syndrome	targetBased	324747	813	0.583744624649583	14
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	postmenopausal atrophic vaginitis	targetBased	86095	1442	0.588528225678562	8
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	postmenopausal atrophic vaginitis	targetBased	86095	1151	0.588528225678562	8
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	hemorrhagic disease	targetBased	217959	2390	0.519130401904105	26
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	anemia	targetBased	359244	2975	0.55367092794918	6
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	dyschromatosis universalis hereditaria	targetBased	362098	692	0.556368558535973	36
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	glaucoma	targetBased	359207	1189	0.588251384537127	9
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	glaucoma	targetBased	63676	1938	0.588251384537127	9
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	glaucoma	targetBased	359207	316	0.588251384537127	9
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	glaucoma	targetBased	63656	2179	0.588251384537127	9
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	glaucoma	targetBased	359207	4555	0.588251384537127	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	glaucoma	targetBased	339297	1446	0.667126406812208	214
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	anovulation	targetBased	86095	1442	0.565777313387203	23
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	anovulation	targetBased	86095	1151	0.565777313387203	23
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	diabetes insipidus	targetBased	324747	813	0.636202273524071	20
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	uterine disorder	targetBased	86095	1442	0.507476068058557	607
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	uterine disorder	targetBased	86095	1151	0.507476068058557	607
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	peptic ulcer disease	targetBased	359207	1189	0.619285523949174	12
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	peptic ulcer disease	targetBased	63676	1938	0.619285523949174	12
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	peptic ulcer disease	targetBased	359207	316	0.619285523949174	12
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	peptic ulcer disease	targetBased	63656	2179	0.619285523949174	12
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	peptic ulcer disease	targetBased	359207	4555	0.619285523949174	12
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	peptic ulcer disease	targetBased	363803	1450	0.60466648961276	9
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	peptic ulcer disease	targetBased	363803	2629	0.60466648961276	9
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	peptic ulcer disease	targetBased	363803	502	0.60466648961276	9
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	peptic ulcer disease	targetBased	363803	698	0.60466648961276	9
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	peptic ulcer disease	targetBased	363803	2133	0.60466648961276	9
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	peptic ulcer disease	targetBased	363803	1081	0.60466648961276	9
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	intestinal obstruction	targetBased	335239	991	0.634364034199603	37
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	intestinal obstruction	targetBased	335239	695	0.634364034199603	37
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	ileus	targetBased	335239	991	0.624516078630663	44
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	ileus	targetBased	335239	695	0.624516078630663	44
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	Tietz syndrome	targetBased	642362	5830	0.865119071324702	993
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	Tietz syndrome	targetBased	331360	2760	0.865119071324702	993
Thrombin 1536 HTS	F2_modulation	thrombophilia due to thrombin defect	targetBased	217233	557	0.805005841741523	84
HCS assay for microtubule stabilizers	TUBB	multiple benign circumferential skin creases on limbs	targetBased	195821	1625	0.723505147515324	25
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	progressive osseous heteroplasia	targetBased	334825	423	0.829331087202839	191
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	progressive osseous heteroplasia	targetBased	337446	1356	0.829331087202839	191
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	congenital afibrinogenemia	targetBased	369953	760	0.876312075943651	206
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	congenital afibrinogenemia	targetBased	369953	498	0.876312075943651	206
Factor XIIa 1536 HTS	F12_modulation	congenital factor XII deficiency	targetBased	217430	649	0.885973348043109	105
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	progressive supranuclear palsy-parkinsonism syndrome	pathwayBased	267412	5703	0.713727143151145	27
qHTS Assay for Tau Filament Binding	MAPT	progressive supranuclear palsy-parkinsonism syndrome	targetBased	69668	1391	0.713727143151145	27
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	progressive supranuclear palsy-parkinsonism syndrome	pathwayBased	271402	1048	0.713727143151145	27
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	congenital bilateral aplasia of vas deferens from CFTR mutation	targetBased	343786	1253	0.869751101269822	953
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	congenital bilateral aplasia of vas deferens from CFTR mutation	targetBased	296501	2737	0.869751101269822	953
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	hemophilia A	targetBased	324747	813	0.577168330395272	6
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	supranuclear palsy, progressive, 1	pathwayBased	267412	5703	0.803558269928458	35
qHTS Assay for Tau Filament Binding	MAPT	supranuclear palsy, progressive, 1	targetBased	69668	1391	0.803558269928458	35
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	supranuclear palsy, progressive, 1	pathwayBased	271402	1048	0.803558269928458	35
qHTS for Inhibitors of WRN Helicase	WRN	Werner syndrome	targetBased	364011	1678	0.907108387719303	6225
qHTS Assay for Identification of Novel General Anesthetics	FTL	hereditary hyperferritinemia with congenital cataracts	targetBased	341499	255	0.86894222650151	294
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	Quebec platelet disorder	targetBased	325247	1021	0.720412492694258	131
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	familial gestational hyperthyroidism	targetBased	329153	670	0.792500474621163	45
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	familial gestational hyperthyroidism	targetBased	329153	670	0.792500474621163	45
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	familial gestational hyperthyroidism	targetBased	72026	352	0.792500474621163	45
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	familial gestational hyperthyroidism	targetBased	72026	1794	0.792500474621163	45
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	age related macular degeneration 7	targetBased	343467	1710	0.598242739303757	8
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	familial pseudohyperkalemia	targetBased	362098	692	0.751304181752444	20
Factor XIIa 1536 HTS	F12_modulation	hereditary angioedema type 3	targetBased	217430	649	0.848320324519467	99
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	retinitis pigmentosa 37	targetBased	362026	1281	0.832806550013503	123
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	retinitis pigmentosa 37	targetBased	314998	380	0.832806550013503	123
Factor XIa 1536 HTS	F11_modulation	congenital factor XI deficiency	targetBased	218707	302	0.928341461537528	543
Thrombin 1536 HTS	F2_modulation	congenital prothrombin deficiency	targetBased	217233	557	0.877708103951809	440
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	premature ovarian failure 7	targetBased	64908	1225	0.830926945955708	29
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	premature ovarian failure 7	targetBased	64908	359	0.830926945955708	29
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY sex reversal 3	targetBased	64908	1225	0.87124875351183	101
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY sex reversal 3	targetBased	64908	359	0.87124875351183	101
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	spermatogenic failure 8	targetBased	64908	1225	0.816032599202828	24
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	spermatogenic failure 8	targetBased	64908	359	0.816032599202828	24
qHTS Assay for Identification of Novel General Anesthetics	FTL	L-ferritin deficiency	targetBased	341499	255	0.67761879609898	14
Colorimetric Assay for Inhibitors for NALP1	NLRP1	corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome	targetBased	280024	1717	0.769399353712043	54
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	reticulate acropigmentation of Kitamura	targetBased	369953	2294	0.725807307099538	20
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	Bartter syndrome	targetBased	125268	2463	0.719032633702922	260
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	familial dysfibrinogenemia	targetBased	369953	760	0.817497971692264	115
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	familial dysfibrinogenemia	targetBased	369953	498	0.817497971692264	115
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	familial hypodysfibrinogenemia	targetBased	369953	760	0.594921821134701	17
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	familial hypodysfibrinogenemia	targetBased	369953	498	0.594921821134701	17
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY partial gonadal dysgenesis	targetBased	64908	1225	0.63355396095555	57
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY partial gonadal dysgenesis	targetBased	64908	359	0.63355396095555	57
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	congenital fibrinogen deficiency	targetBased	369953	760	0.589911108501056	90
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	congenital fibrinogen deficiency	targetBased	369953	498	0.589911108501056	90
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	Waardenburg syndrome	targetBased	642362	5830	0.710068003690276	557
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	Waardenburg syndrome	targetBased	331360	2760	0.710068003690276	557
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	familial idiopathic steroid-resistant nephrotic syndrome	targetBased	305610	382	0.707847255095907	233
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	familial idiopathic steroid-resistant nephrotic syndrome	targetBased	305610	3253	0.707847255095907	233
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	congenital bilateral absence of vas deferens	targetBased	343786	1253	0.773298478345554	346
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	congenital bilateral absence of vas deferens	targetBased	296501	2737	0.773298478345554	346
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	progressive supranuclear palsy	pathwayBased	267412	5703	0.732176008180037	68
qHTS Assay for Tau Filament Binding	MAPT	progressive supranuclear palsy	targetBased	69668	1391	0.732176008180037	68
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	progressive supranuclear palsy	pathwayBased	271402	1048	0.732176008180037	68
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	Waardenburg syndrome type 2	targetBased	642362	5830	0.701605857510609	495
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	Waardenburg syndrome type 2	targetBased	331360	2760	0.701605857510609	495
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Turner syndrome	targetBased	86095	1442	0.606613111606686	26
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Turner syndrome	targetBased	86095	1151	0.606613111606686	26
Factor XIa 1536 HTS	F11_modulation	hereditary angioedema	targetBased	218707	302	0.586599784505418	14
Factor XIIa 1536 HTS	F12_modulation	hereditary angioedema	targetBased	217430	649	0.800372299981284	87
Thrombin 1536 HTS	F2_modulation	prothrombin deficiency	targetBased	217233	557	0.764218597299019	588
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	chronic renal failure syndrome	targetBased	394050	3624	0.595650699705387	9
Factor XIa 1536 HTS	F11_modulation	factor XI deficiency	targetBased	218707	302	0.855157966549838	264
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY disorder of sex development	targetBased	64908	1225	0.697883070713665	226
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY disorder of sex development	targetBased	64908	359	0.697883070713665	226
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	retinitis pigmentosa 92	targetBased	340696	540	0.626498224873465	11
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Ataxia-telangiectasia	targetBased	322361	619	0.965192627517889	20484
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX testicular disorder of sex development	targetBased	64908	1225	0.615040310401099	39
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XX testicular disorder of sex development	targetBased	64908	359	0.615040310401099	39
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	BOR syndrome	targetBased	364053	2026	0.508497845130564	95
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	Goldmann-Favre syndrome	targetBased	362026	1281	0.671491858896114	78
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	Goldmann-Favre syndrome	targetBased	314998	380	0.671491858896114	78
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	hemorrhage	targetBased	86095	1442	0.618589591189615	43
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	hemorrhage	targetBased	86095	1151	0.618589591189615	43
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	Benign familial neonatal seizures	targetBased	305609	3405	0.933986431041984	515
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	Benign familial neonatal seizures	targetBased	305600	1644	0.933986431041984	515
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	hemorrhage	targetBased	324747	813	0.648280443805337	36
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	hemorrhage	targetBased	339297	1446	0.621256851051645	22
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	hemorrhage	targetBased	369953	760	0.612062449884587	18
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	hemorrhage	targetBased	369953	498	0.612062449884587	18
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	hemorrhage	targetBased	324747	1043	0.638135094889748	55
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	hemorrhage	targetBased	361330	3713	0.655846725244634	54
Allosteric Modulators of D1 Receptors: Primary Screen	D1	hemorrhage	targetBased	57705	3413	0.655846725244634	54
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	hemorrhage	targetBased	355805	11440	0.655846725244634	54
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	hemorrhage	targetBased	316642	617	0.543561973515538	7
qHTS for Inhibitors of TGF-b	TGFB1	Beta-thalassemia	pathwayBased	403345	4970	0.520897841651956	12
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	Familial exudative vitreoretinopathy	targetBased	193542	587	0.780174169924281	54
Thrombin 1536 HTS	F2_modulation	Congenital factor II deficiency	targetBased	217233	557	0.848343511620626	104
qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1)	TDP1	Spinocerebellar ataxia type 1 with axonal neuropathy	targetBased	344442	978	0.507687855850537	23
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT	TDP1	Spinocerebellar ataxia type 1 with axonal neuropathy	targetBased	416824	63248	0.507687855850537	23
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT	TDP1	Spinocerebellar ataxia type 1 with axonal neuropathy	targetBased	416856	49238	0.507687855850537	23
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	Cytomegalic congenital adrenal hypoplasia	targetBased	368927	4094	0.848222789812202	44
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	Cytomegalic congenital adrenal hypoplasia	targetBased	343468	3417	0.848222789812202	44
Colorimetric Assay for Inhibitors for NALP1	NLRP1	Corneal intraepithelial dyskeratosis with palmoplantar hyperkeratosis and laryngeal dyskeratosis	targetBased	280024	1717	0.7275973224838	33
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	Conjunctival telangiectasia	targetBased	322361	619	0.570511616340399	6831
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Familial afibrinogenemia	targetBased	369953	760	0.849937604123244	24
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Familial afibrinogenemia	targetBased	369953	498	0.849937604123244	24
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	Fuchs endothelial corneal dystrophy	targetBased	59788	212	0.527795610915018	9

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	refractory plasma cell neoplasm	THALIDOMIDE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT00112879	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fragile X syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fragile X syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fragile X syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fragile X syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fragile X syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fragile X syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fragile X syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	Down syndrome	DEXTROTHYROXINE	targetBased	3	Completed	02/04/2012	https://clinicaltrials.gov/study/NCT01576705	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	trichotillomania	NALTREXONE	targetBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00775229	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	trichotillomania	NALTREXONE	targetBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00775229	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	trichotillomania	NALTREXONE	targetBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00775229	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Familial paroxysmal ataxia	DALFAMPRIDINE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT01543750	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Familial paroxysmal ataxia	DALFAMPRIDINE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT01543750	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Familial paroxysmal ataxia	DALFAMPRIDINE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT01543750	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Familial paroxysmal ataxia	DALFAMPRIDINE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT01543750	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Familial paroxysmal ataxia	DALFAMPRIDINE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT01543750	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Familial paroxysmal ataxia	DALFAMPRIDINE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT01543750	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Familial paroxysmal ataxia	DALFAMPRIDINE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT01543750	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	trichotillomania	OLANZAPINE	targetBased	4	Completed	01/06/2000	https://clinicaltrials.gov/study/NCT00182507	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	autosomal dominant Ehlers-Danlos syndrome, vascular type	CELIPROLOL	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00190411	1	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	fragile X syndrome	METHYLPHENIDATE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Down syndrome	MEMANTINE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT01112683	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		fragile X syndrome	MEMANTINE	targetBased	2	Recruiting	08/09/2022	https://clinicaltrials.gov/study/NCT05418049	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	mitochondrial disease	BEZAFIBRATE	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02398201	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	mitochondrial disease	BEZAFIBRATE	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02398201	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	mitochondrial disease	BEZAFIBRATE	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02398201	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	mitochondrial disease	BEZAFIBRATE	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02398201	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	mitochondrial disease	BEZAFIBRATE	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02398201	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	mitochondrial disease	BEZAFIBRATE	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02398201	0.2	GoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1	DABIGATRAN	targetBased	2	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT01361763	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	mitochondrial disease	BUPROPION	targetBased	1	Completed	10/11/2020	https://clinicaltrials.gov/study/NCT04643249	0.1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	stutter disorder	ECOPIPAM	targetBased	2	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT02909088	0.2	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	stutter disorder	ECOPIPAM	targetBased	2	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT02909088	0.2	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	stutter disorder	ECOPIPAM	targetBased	2	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT02909088	0.2	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	stutter disorder	ECOPIPAM	targetBased	2	Completed	02/10/2020	https://clinicaltrials.gov/study/NCT04492956	0.2	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	stutter disorder	ECOPIPAM	targetBased	2	Completed	02/10/2020	https://clinicaltrials.gov/study/NCT04492956	0.2	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	stutter disorder	ECOPIPAM	targetBased	2	Completed	02/10/2020	https://clinicaltrials.gov/study/NCT04492956	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fragile X syndrome	ARIPIPRAZOLE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00420459	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fragile X syndrome	ARIPIPRAZOLE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00420459	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fragile X syndrome	ARIPIPRAZOLE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00420459	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fragile X syndrome	ARIPIPRAZOLE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00420459	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fragile X syndrome	ARIPIPRAZOLE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00420459	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fragile X syndrome	ARIPIPRAZOLE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00420459	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	fragile X syndrome	ARIPIPRAZOLE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00420459	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	fragile X syndrome	ARIPIPRAZOLE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00420459	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fragile X syndrome	ARIPIPRAZOLE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00420459	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	dermatitis, atopic	SB-705498	targetBased	1	Completed	17/07/2012	https://clinicaltrials.gov/study/NCT01673529	0.1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Down syndrome	TOFACITINIB	targetBased	2	Recruiting	29/06/2023	https://clinicaltrials.gov/study/NCT05662228	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	dermatitis, atopic	TOFACITINIB	targetBased	2	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02001181	0.2	LoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	Monosomy 22q13	OXYTOCIN	targetBased	2	Completed	29/04/2016	https://clinicaltrials.gov/study/NCT02710084	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	fragile X syndrome	OXYTOCIN	targetBased	2	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT01254045	0.2	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	dermatitis, atopic	TAPINAROF	targetBased	2	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01098734	0.2	GoF	protect
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	AHR	Aryl hydrocarbon receptor	dermatitis, atopic	TAPINAROF	targetBased	1	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00837551	0.1	GoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	refractory plasma cell neoplasm	ARSENIC TRIOXIDE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT00112879	0.2	LoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	refractory plasma cell neoplasm	ARSENIC TRIOXIDE	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT00085345	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		fragile X syndrome	ACAMPROSATE	targetBased	2	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01300923	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		fragile X syndrome	ACAMPROSATE	targetBased		Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02998151	0.05	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		fragile X syndrome	ACAMPROSATE	targetBased	1	Completed	27/08/2013	https://clinicaltrials.gov/study/NCT01911455	0.1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dermatitis, atopic	EFALIZUMAB	targetBased	1	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00226057	0.1	LoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	dermatitis, atopic	EFALIZUMAB	targetBased	2	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00146003	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	fragile X syndrome	ERGOLOID MESYLATES	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	fragile X syndrome	ERGOLOID	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT05030129	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	stutter disorder	ASENAPINE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	Bardet-Biedl syndrome	SETMELANOTIDE	targetBased	3	Completed	16/02/2022	https://clinicaltrials.gov/study/NCT04966741	0.7	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	Bardet-Biedl syndrome	SETMELANOTIDE	targetBased	3	Completed	16/02/2022	https://clinicaltrials.gov/study/NCT04966741	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	stutter disorder	ASENAPINE MALEATE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE MALEATE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE MALEATE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE MALEATE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE MALEATE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE MALEATE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	stutter disorder	ASENAPINE MALEATE	targetBased	3	Suspended	01/09/2012	https://clinicaltrials.gov/study/NCT01684657	0.7	LoF	protect	Study transferring to another facility
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	MAPK1	Mitogen-activated protein kinase 1	histiocytic neoplasm	ULIXERTINIB	pathwayBased	2	Recruiting	07/05/2024	https://clinicaltrials.gov/study/NCT06411821	0.2	LoF	protect
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	MAPK1	Mitogen-activated protein kinase 1	histiocytic neoplasm	ULIXERTINIB	pathwayBased	2	Recruiting	07/05/2024	https://clinicaltrials.gov/study/NCT06411821	0.2	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Wolfram syndrome	TIRZEPATIDE	targetBased	2	Recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT05659368	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Wolfram syndrome	TIRZEPATIDE	targetBased	2	Recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT05659368	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	Wolfram syndrome	TIRZEPATIDE	targetBased	2	Recruiting	01/01/2024	https://clinicaltrials.gov/study/NCT05659368	0.2	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	dermatitis, atopic	GUSACITINIB	targetBased	1	Completed	12/04/2017	https://clinicaltrials.gov/study/NCT03139981	0.1	LoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.